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Abstract
Purpose: To assess the patterns of statin therapy prescribing among hospitalized patients with type 2 diabetes mellitus
(T2DM) in two Malaysian tertiary healthcare institutions and to determine compliance with Malaysian treatment
guidelines. Methods: A cross-sectional study was conducted from September to December 2016. The study involved
hospitalized T2DM patients aged between 40 to 75 years recruited from the medical wards of two tertiary hospitals in
the state of Pahang, Malaysia. Evaluation of statin prescribing was classified as appropriate (statin therapy was
prescribed with no concurrent drug interactions) or inappropriate (not receiving any statins, although no
contraindications), or potentially inappropriate (drug interactions detected or renal dose adjustment needed). Results:
Among the 393 medical records screened, 65 % had a statin therapy prescription. The evaluation of statins prescribing
showed that approximately 35 % of patients were not prescribed statins, contrary to national treatment guidelines.
Twenty-six percent of the study cases were given drugs that interacted with statins. Renal dose adjustment of the given
statin was needed in 5 % of patients. Finally, only one-third of the patients were prescribed appropriate statin doses.
Conclusion: A significant portion of T2DM hospitalized patients did not receive their recommended statin therapy for
cardiovascular disease prophylaxis. Closer monitoring and further dose adjustments are warranted to optimize statin
therapy prescribing. Further interventions to improve statin prescribing should be considered. © 2017 The authors &
Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria.
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